[Hepatitis B and hepatitis C, a high stake for public health: how to reconcile health cost control and public health expenses?].
D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control; D003363:Cost Control; D018450:Disease Progression; D005060:Europe / Q000453:epidemiology; D005602:France / Q000453:epidemiology; D006509:Hepatitis B / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000191:economics; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007223:Infant; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D008403:Mass Screening / Q000191:economics; D011634:Public Health / Q000191:economics*
D000998:Antiviral Agents; D017325:Hepatitis B Vaccines